22 min
Genome Editing: Fetal Origins of AML in Down Syndrome, With Drs. Adam Mead & Elvin Wagenblast The Hematologist
-
- Science
Contributing Editor Dr. Adam Mead has a conversation with Dr. Elvin Wagenblast about a study that used CRISPR/Cas9 genome editing of hematopoietic stem and progenitor cells from human fetal liver to induce transient abnormal myelopoiesis– and myeloid leukemia associated with Down syndrome–related mutations.
Contributing Editor Dr. Adam Mead has a conversation with Dr. Elvin Wagenblast about a study that used CRISPR/Cas9 genome editing of hematopoietic stem and progenitor cells from human fetal liver to induce transient abnormal myelopoiesis– and myeloid leukemia associated with Down syndrome–related mutations.
22 min